David S. Grayzel - 12 Jun 2026 Form 4/A - Amendment Insider Report for Q32 Bio Inc. (QTTB)

Reporting relationship: Director
Issuer ticker: QTTB
Reported as of: 12 Jun 2026
Net transaction value: $0
SEC form: 4/A - Amendment
Accepted by SEC: 21 Jul 2026, 20:24:19 UTC
Original report date: 16 Jun 2026
Prior SEC filing: 30 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Eric Bell, Attorney-in-Fact

Key filing fact

David S. Grayzel filed Form 4/A - Amendment for Q32 Bio Inc. (QTTB) on 21 Jul 2026.

Key facts

This page summarizes David S. Grayzel's Form 4/A - Amendment filing for Q32 Bio Inc. (QTTB).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 21 Jul 2026, 20:24.

Change

Previous filing in this sequence was filed on 30 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0001732786 Primary reporting owner

GRAYZEL DAVID S.

Relationship: Director
Address: Q32 BIO INC., 830 WINTER STREET, WALTHAM
Signature: /s/ Eric Bell, Attorney-in-Fact
Signature date: 21 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

QTTB transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +10,826
Change %
Price: $0.000000^*
Shares after: 10,826
Date: 12 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,826
Exercise price: $12.64
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026.

Footnote F2

The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

Footnote F3

This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.